EMA finds potential link between AstraZeneca Covid-19 vaccine and blood clots
The European Medicines Agency said on Wednesday it had found a potential link between AstraZeneca's Covid-19 vaccine and blood clots in adults who had received the shot.
The EMA said it had taken into consideration all available evidence, according to Reuters.
“One plausible explanation for the combination of blood clots and low blood platelets is an immune response, leading to a condition similar to one seen sometimes in patients treated with heparin,” the watchdog said in a statement.
The regulator had backed the vaccine up until the prior week, saying there was no evidence of risk of blood clotting in general.
The news was a blow for the pharma company which is one of the most popular choices when it comes to acquiring shots to treat the illness.
EMA’s safety committee, which was assessing the shot, had requested for more studies and changes to the current ones to get more information.
Important Legal Notice about News Sources: Pilling and Co Stockbrokers Ltd. is not responsible for the content or accuracy of third party news and we may not share the views of the author or publisher. We provide third party news for your convenience and information only and make no representation or endorsement whatsoever and hereby exclude all liability for any loss or damage that may be incurred by you as a result of your access or use. Please note that third party content may be subject to terms and conditions imposed by the third party owner of that content.